A Phase 1 interventional study of PF-04965842 in Hepatic Impairment, sponsored by Pfizer. Completed at 2 sites in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-05-18.
Sponsored by Pfizer · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a Phase 1 non randomized, open label, single dose, parallel cohort study to investigate the effect of hepatic impairment on the PK, safety and tolerability of PF 04965842.
A minimum of 24 subjects with normal, mild or moderate hepatic function will be enrolled into the study, with approximately 8 subjects in each cohort. The Child Pugh classification score will be utilized to assess entry criteria and to assign subjects into the appropriate hepatic impairment group. For individual subjects, the total maximum duration of study participation from the Screening visit to the end of clinical research unit (CRU) stay is approximately 31 days and approximately 63 days from the Screening visit to the Follow up contact.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Additional Inclusion Criteria for subjects with hepatic impairment:
Exclusion Criteria:
Additional exclusion criteria for subjects with hepatic impairment:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PF 04965842 is an orally bioavailable small molecule that selectively inhibits JAK1.
Drug: PF-04965842
PF 04965842 is an orally bioavailable small molecule that selectively inhibits JAK1.
Maximum Observed Plasma Concentration (Cmax) for PF-04965842
Cmax is maximum plasma concentration. It was observed directly from data.
Time frame: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 14, 24, 36, 48, 72 hours post-dose in each cohort
Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUCinf) for PF-04965842
AUCinf is area under the concentration-time curve (AUC) from time 0 (pre-dose) extrapolated to infinite time.
Time frame: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 10, 14, 24, 36, 48, 72 hours post-dose in each cohort
Number of Participants With Treatment-Emergent Adverse Events (AEs) for PF-04965842
Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Treatment-emergent adverse events (TEAEs) were those with initial onset or increasing in severity between the first dose of investigational product and up to 36 days post-dose.
Time frame: From screening (within 28 days prior to Day 1) till up to 36 days post-dose, the total maximum duration was approximately 63 days for individual participants.
Number of Participants With Laboratory Test Abnormalities (Without Regard to Baseline Abnormality)
Laboratory tests included tests that were performed under the categories of hematology, chemistry, urinalysis, other, and additional tests needed for Hy's law.
Time frame: Screening (within 28 days prior to Day 1), Day -1, 2, 24, 72 hours post-dose.
Number of Participants With Electrocardiogram (ECG) Findings of Potential Clinical Importance for PF-04965842
12-Lead ECGs were collected after the participants rested quietly for at least 10 minutes in a supine position. Clinical significance of ECG recordings was determined at the investigator's discretion.
Time frame: Screening (within 28 days prior to Day 1), Day -1, 2, 72 hours post-dose.
Number of Participants With Vital Sign Findings of Potential Clinical Importance for PF-04965842
Vital signs (pulse rate, systolic and diastolic blood pressure) were obtained with participant following at least 5 minutes of supine rest. Clinical significance of vital signs was determined at the investigator's discretion.
Time frame: Screening (within 28 days prior to Day 1), 0 (pre-dose), and 72 hours post-dose.
| Milestone | PF-04965842 (Normal Hepatic Function Cohort) | PF-04965842 (Mild Hepatic Impairment Cohort) | PF-04965842 (Moderate Hepatic Impairment Cohort) |
|---|---|---|---|
| Started | 8 | 8 | 8 |
| Completed | 8 | 8 | 8 |
| Not completed | 0 | 0 | 0 |
Cmax is maximum plasma concentration. It was observed directly from data.
| nanogram per milliliter (ng/mL) | PF-04965842 (Normal Hepatic Function Cohort) | PF-04965842 (Mild Hepatic Impairment Cohort) | PF-04965842 (Moderate Hepatic Impairment Cohort) |
|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) for PF-04965842 | 1352 ± 44 | 1276 ± 41 | 1426 ± 63 |
AUCinf is area under the concentration-time curve (AUC) from time 0 (pre-dose) extrapolated to infinite time.
| nanogram*hour per milliliter (ng*hr/mL) | PF-04965842 (Normal Hepatic Function Cohort) | PF-04965842 (Mild Hepatic Impairment Cohort) | PF-04965842 (Moderate Hepatic Impairment Cohort) |
|---|---|---|---|
| Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUCinf) for PF-04965842 | 5587 ± 74 | 7449 ± 29 | 8603 ± 55 |
Cmax,u is unbound Cmax. The active moiety is comprised of parent drug PF-04965842, active metabolites PF-06471658 and PF-07055087.
| nanomolar (nM) | PF-04965842 (Normal Hepatic Function Cohort) | PF-04965842 (Mild Hepatic Impairment Cohort) | PF-04965842 (Moderate Hepatic Impairment Cohort) |
|---|---|---|---|
| Unbound Cmax (Cmax,u) for Active Moiety | 2390 ± 20 | 1815 ± 36 | 2011 ± 41 |
AUCinf,u is unbound AUCinf. The active moiety is comprised of parent drug PF-04965842, active metabolites PF-06471658 and PF-07055087.
| nanomolar*hour (nM*hr) | PF-04965842 (Normal Hepatic Function Cohort) | PF-04965842 (Mild Hepatic Impairment Cohort) | PF-04965842 (Moderate Hepatic Impairment Cohort) |
|---|---|---|---|
| Unbound AUCinf (AUCinf,u) for Active Moiety | 12010 ± 40 | 11500 ± 24 | 13790 ± 30 |
Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Treatment-emergent adverse events (TEAEs) were those with initial onset or increasing in severity between the first dose of investigational product and up to 36 days post-dose.
| Participants | PF-04965842 (Normal Hepatic Function Cohort) | PF-04965842 (Mild Hepatic Impairment Cohort) | PF-04965842 (Moderate Hepatic Impairment Cohort) |
|---|---|---|---|
| AEs (all causalities) | 2 | 3 | 0 |
| AEs (treatment related) | 1 | 3 | 0 |
Laboratory tests included tests that were performed under the categories of hematology, chemistry, urinalysis, other, and additional tests needed for Hy's law.
| Participants | PF-04965842 (Normal Hepatic Function Cohort) | PF-04965842 (Mild Hepatic Impairment Cohort) | PF-04965842 (Moderate Hepatic Impairment Cohort) |
|---|---|---|---|
| Number of Participants With Laboratory Test Abnormalities (Without Regard to Baseline Abnormality) | 4 | 7 | 8 |
12-Lead ECGs were collected after the participants rested quietly for at least 10 minutes in a supine position. Clinical significance of ECG recordings was determined at the investigator's discretion.
| Participants | PF-04965842 (Normal Hepatic Function Cohort) | PF-04965842 (Mild Hepatic Impairment Cohort) | PF-04965842 (Moderate Hepatic Impairment Cohort) |
|---|---|---|---|
| Number of Participants With Electrocardiogram (ECG) Findings of Potential Clinical Importance for PF-04965842 | 0 | 0 | 0 |
Vital signs (pulse rate, systolic and diastolic blood pressure) were obtained with participant following at least 5 minutes of supine rest. Clinical significance of vital signs was determined at the investigator's discretion.
| Participants | PF-04965842 (Normal Hepatic Function Cohort) | PF-04965842 (Mild Hepatic Impairment Cohort) | PF-04965842 (Moderate Hepatic Impairment Cohort) |
|---|---|---|---|
| Number of Participants With Vital Sign Findings of Potential Clinical Importance for PF-04965842 | 0 | 0 | 0 |
Collected over From screening (within 28 days prior to Day 1) till up to 36 days post-dose, the total maximum duration was approximately 63 days for individual participants.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PF-04965842 (Normal Hepatic Function Cohort) | 0/8 (0%) | 0/8 (0%) | 2/8 (25%) |
| PF-04965842 (Mild Hepatic Impairment Cohort) | 0/8 (0%) | 0/8 (0%) | 3/8 (37.5%) |
| PF-04965842 (Moderate Hepatic Impairment Cohort) | 0/8 (0%) | 0/8 (0%) | 0/8 (0%) |
| Event | PF-04965842 (Normal Hepatic Function Cohort) | PF-04965842 (Mild Hepatic Impairment Cohort) | PF-04965842 (Moderate Hepatic Impairment Cohort) |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 0/8 | 2/8 | 0/8 |
| HeadacheNervous system disorders | 0/8 | 2/8 | 0/8 |
| NauseaGastrointestinal disorders | 1/8 | 0/8 | 0/8 |
| Upper respiratory tract infectionInfections and infestations | 1/8 | 0/8 | 0/8 |
The baseline analysis population included all participants enrolled in the study.
| Age, Continuous(Years) | PF-04965842 (Normal Hepatic Function Cohort) | PF-04965842 (Mild Hepatic Impairment Cohort) | PF-04965842 (Moderate Hepatic Impairment Cohort) | Total |
|---|---|---|---|---|
| Mean | 58.5 ± 5.86 | 57.9 ± 4.19 | 58.6 ± 8.21 | 58.3 ± 6.03 |
| Sex: Female, Male(Participants) | PF-04965842 (Normal Hepatic Function Cohort) | PF-04965842 (Mild Hepatic Impairment Cohort) | PF-04965842 (Moderate Hepatic Impairment Cohort) | Total |
|---|---|---|---|---|
| Female | 3 | 3 | 3 | 9 |
| Male | 5 | 5 | 5 | 15 |
| Ethnicity (NIH/OMB)(Participants) | PF-04965842 (Normal Hepatic Function Cohort) | PF-04965842 (Mild Hepatic Impairment Cohort) | PF-04965842 (Moderate Hepatic Impairment Cohort) | Total |
|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 0 | 1 |
| Not Hispanic or Latino | 7 | 8 | 8 | 23 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | PF-04965842 (Normal Hepatic Function Cohort) | PF-04965842 (Mild Hepatic Impairment Cohort) | PF-04965842 (Moderate Hepatic Impairment Cohort) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 1 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 4 | 0 | 5 |
| White | 7 | 4 | 7 | 18 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Ran from Oct 2018 to primary completion in Apr 2019, 6 months.
Results were first posted in May 2020, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abrocitinib